BioLife Solutions Inc. (BLFS) — Analysis Summary
BioLife Solutions Inc. (BLFS) has a market cap of $1.40B with year-over-year revenue growth of +17.0%. Net margin stands at -4.8%. The stock trades at a P/E ratio of -472.7.
Key Takeaways
- Revenue changed +17.0% year-over-year
- Net margin of -4.8%
- P/E ratio of -472.7
Compared to other companies in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector, BLFS posted revenue growth of +17.0% and trades at a P/E of -472.7.
BioLife Solutions Inc. (BLFS)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Operating margin at -15.4% — material operating losses
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Employees
155
Headquarters
BOTHELL, WA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.